Details:
VB10.16 is an off-the-shelf therapeutic cancer vaccine specifically designed to treat HPV16-induced malignancies. Under the terms of the agreement, Merck will supply KEYTRUDA. Nykode retains all commercial rights to VB10.16 worldwide.
Lead Product(s): VB10.16,Pembrolizumab
Therapeutic Area: Oncology Product Name: VB10.16
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: MSD Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 06, 2022
Details:
Humalutin® (177Lu-DOTA-NNV003), acts by inducing potentially cytotoxic DNA breaks in the NHL cells, sensitising these cells to olaparib, which prevents repair of DNA breaks by blocking activity of DNA repair enzymes poly (ADP ribose) polymerase 1 and 2 (PARP1 and PARP2).
Lead Product(s): 177Lu-DOTA-NNV003,Olaparib
Therapeutic Area: Oncology Product Name: Humalutin
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
This collaboration is an additional mark of interest from a cutting-edge biotech company developing therapies with emerging advanced technologies, with a large potential in future medicine
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: MDimune
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 05, 2022
Details:
Company's decision not to enter into a definitive agreement is primarily based on a strategic evaluation of current development needs. Results have continued to be achieved with the fimaNAc platform in the collaboration.
Lead Product(s): Nucleic acid therapeutics
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 21, 2020
Details:
Alpha37 is an investigational radioimmunoconjugate developed by Nordic Nanovector in collaboration with Orano Med comprising a proprietary chimeric CD37-targeting antibody conjugated to the alpha-particle generating radionuclide lead-212.
Lead Product(s): Alpha37
Therapeutic Area: Oncology Product Name: Alpha37
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020